Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $90.00 price target on Gilead Sciences (NASDAQ: GILD) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Rumors

AstraZeneca (AZN) PT Raised to $60 at CowenJune 10, 2020 8:45 AM AstraZeneca (AZN) and Gilead Sciences (GILD) not in deal talks, but may have been CEO-to-CEO approach - CNBC's FaberJune 8, 2020 9:17 AM Gilead Sciences (GILD) Pipeline Unaffected in Potential Merger Scenario - RBC Capital June 8, 2020 7:24 AM Gilead Sciences (GILD) Gains 3% on Report AstraZeneca (AZN) Approached About a MergerJune 8, 2020 6:18 AM Gilead Sciences (GILD) option implied flat into reports AstraZeneca (AZN) approachesJune 8, 2020 4:38 AM Gilead Sciences (GILD) call put ratio 33 calls to 1 put into approaches Gilead (GILD) about potential merger, Bloomberg saysJune 8, 2020 4:34 AM European stocks take a breather as tech, healthcare weighJune 8, 2020 3:32 AM AstraZeneca, Gilead merger doubted by Wall Street analystsJune 8, 2020 3:20 AM AstraZeneca contacted Gilead over potential megamerger: Bloomberg NewsJune 7, 2020 4:21 AM